David Bautz's questions to Abeona Therapeutics Inc (ABEO) leadership • Q1 2025
Question
David Bautz of Zacks Small-Cap Research asked for details on the billing and reimbursement workflow, including the expected time from patient treatment to payment, and questioned the specific intentions of the 30 patients who have contacted the company.
Answer
Chief Commercial Officer Dr. Madhav Vasanthavada explained that revenue is recognized after treatment, with payment timing on par with other cell and gene therapies, and reimbursement is secured before treatment begins. He clarified that the patient inquiries were general expressions of interest to "get in the queue" before a specific QTC was announced. CEO Dr. Vish Seshadri added this pre-authorization process explains the lead time before the first patient treatment.